Patient Characteristics
| Characteristic | 90Y-glass | 90Y-resin | 166Ho | P* | Significant pair |
|---|---|---|---|---|---|
| Patients | 6 | 8 | 7 | ||
| Age (y) | 64.5 (32–80) | 61.5 (43–81) | 59 (45–83) | 0.87 | |
| Sex | 0.94 | ||||
| Male | 24 | 3 | 2 | ||
| Female | 5 | 5 | |||
| Liver volume (cm3) | 2,077 (1,636–2,631) | 1,842 (1,231–2,182) | 2,261 (1,725–4,019) | 0.22 | |
| Tumors | 7 | 24 | 11 | 0.31 | |
| Tumor volume (cm3) | 100 (10–470) | 156 (36–398) | 146 (16–2,655) | 0.73 | |
| Total TLG (106) | 0.60 (0.09–5.8) | 1.2 (0.27–5.6) | 1.2 (0.11–24) | 0.77 | |
| Type of radioembolization treatment | 0.01 | 90Y-glass vs. 90Y-resin | |||
| Whole liver | 0 | 8 | 4 | ||
| Lobar | 5 | 0 | 2 | ||
| Superselective | 1 | 0 | 1 | ||
| Previous treatments | 0.38 | ||||
| Chemotherapy | 2 | 4 | 5 | ||
| Surgery | 1 | 0 | 0 | ||
| Chemotherapy + surgery | 1 | 3 | 0 | ||
| Chemotherapy + radioembolization | 1 | 0 | 0 | ||
| Surgery + radioembolization | 0 | 0 | 1 | ||
| None | 1 | 1 | 1 | ||
| ECOG performance status | 0.71 | ||||
| 0 | 5 | 7 | 5 | ||
| 1 | 1 | 1 | 1 | ||
| 2 | 0 | 0 | 1 | ||
| Administered activity (MBq) | 2,273 (894–4,503) | 1,541 (729–1,943) | 6,568 (2,391–12,897) | 0.01 | 90Y-glass vs. 166Ho; 90Y-resin vs. 166Ho |
| Activity at posttreatment acquisition (MBq) | 1,818 (735–3,536) | 1,397 (596–1,697) | 324 (156–374) | 0.01 | 90Y-glass vs. 166Ho; 90Y-resin vs. 166Ho |
| LSF on planar [99mTc]MAA imaging | 3.5% (1.9%–11.7%) | 2.2% (0.8%–14.8%) | 4.4% (1.6%–13.4%) | 0.15 |
↵* Numeric variables were assessed with Kruskal–Wallis H and Mann–Whitney U tests. For categoric variables, χ2 tests were used.
ECOG = Eastern Cooperative Oncology Group.
Qualitative data are number; continuous data are median and range.